ATAI News and Press, ATAI Life Sciences N.V. From 09/14/21

NEW YORK and BERLIN, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Perception Neuroscience (Perception), an atai Life Sciences (atai) biopharmaceutical company focused on developing innovative therapies in neuropsychiatric diseases, today announced the initiation of a Phase 2a clinical study to ev...

BERLIN and SAN DIEGO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences (Nasdaq: ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, and its digital therapeutic platform Introspect Digital Therapeutic...

BERLIN, Sept. 03, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it will participate in in the following upcoming inves...

Atai Life Sciences N.V. (ATAI) Q2 2021 Earnings Conference Call August 16, 2021 08:30 ET Company Participants Greg Weaver - Chief Financial Officer Florian Brand - Chief Executive Officer Srinivas Rao - Co-Founder & Chief Scientific Officer Christian Angermayer - Founder & Chairman Co...

-Successfully completed Initial Public Offering on Nasdaq raising $258.8 million in gross proceeds, including the underwriters’ over-allotment- -Received $20 million upfront payment from Otsuka as part of the first major collaboration between a biopharmaceutical company d...

BERLIN, Aug. 12, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences (Nasdaq: ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced the launch of Revixia Life Sciences (Revixia), a wholly owned subsidiary...

BERLIN, Aug. 09, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it plans to host a conference call on Monday, August 16, 202...

BERLIN, Aug. 06, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it will participate in a fireside chat and one-on-one invest...

Psychedelics, like psilocybin could soon revolutionize the treatment of mental and health issues, including obesity. At the moment, worldwide obesity has tripled since 1975, says the World Health Organization. Plus, as of 2016, more than 1.9 billion adults were considered overweight, with 6...

An increasing number of cities are considering reforming laws that would effectively decriminalize the use of psychedelic drugs for recreational use, Marijuana Moment reports. The latest cities to consider such measures include Easthampton, Mass.; Grand Rapids, Mich.; and Arcata, Calif. Refor...